Phaseline

Targets › PDE5A

PDE5A (cGMP-specific 3',5'-cyclic phosphodiesterase): drug programs, companies and trials

32 programs from 31 companies in 40 trials: 16 Phase 2, 11 Phase 4, 9 Phase 3, 4 Phase 1; Cardiovascular, Genitourinary, Other; next expected readout Nov 2026.

Plays a role in signal transduction by regulating the intracellular concentration of cyclic nucleotides. This phosphodiesterase catalyzes the specific hydrolysis of cGMP to 5'-GMP. Specifically regulates nitric-oxide-generated cGMP. (UniProt, O76074)

Open in Phaseline: the race on PDE5A, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Beni-Suef UniversityTadalafil
Phosphodiesterase 5A inhibitor
PDE5APhase 4IVF; Erectile Dysfunction; Acute Urinary RetentionNov 2026
St Joseph University, Beirut, LebanonPentoxifylline
Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor
ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3APhase 4Lumbar RadiculopathyDec 2026
Mansoura UniversityTadalafil
Phosphodiesterase 5A inhibitor
PDE5APhase 4Overactive Bladder (OAB); Erectile Dysfunctions; Erectile DysfunctionDec 2026
The Netherlands Cancer InstituteSildenafil
Phosphodiesterase 5A inhibitor
PDE5APhase 4Erectile Dysfunction Following Radical ProstatectomyJan 2027
VA Office of Research and DevelopmentPentoxifylline
Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor
ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3APhase 4Diabetic Kidney DiseaseJan 2028
University of Sao Paulo General HospitalSildenafil
Phosphodiesterase 5A inhibitor
PDE5APhase 4Pulmonary Arterial Hypertension (PAH)Jul 2028
Vastra Gotaland RegionDipyridamole
Equilibrative nucleoside transporter 1 inhibitor; 3',5'-cyclic phosphodiesterase inhibitor
SLC29A1, PDE5A, PDE4A, PDE3A, PDE6HPhase 4Takotsubo SyndromeDec 2028
Eric A. HoffmanSildenafil
Phosphodiesterase 5A inhibitor
PDE5APhase 4Emphysema–
Al-Azhar UniversityPentoxifylline
Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor
ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3APhase 3Chronic Kidney DiseasesDec 2026
Tanta UniversityPentoxifylline
Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor
ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3APhase 3IBS - Irritable Bowel Syndrome; Rheumatoid ArthritisMay 2027
Assistance Publique - Hôpitaux de ParisTadalafil
Phosphodiesterase 5A inhibitor
PDE5APhase 3Pulmonary Hypertension; Pulmonary Arterial Hypertension (PAH)Oct 2027
University Hospital, RouenSildenafil
Phosphodiesterase 5A inhibitor
PDE5APhase 3Rectal CancerFeb 2030
University of WashingtonPentoxifylline
Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor
ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3APhase 3Medication-related Osteonecrosis of the Jaw–
Rennes University HospitalSildenafil citrate
Phosphodiesterase 5A inhibitor
PDE5APhase 3Peripheral Artery Disease–
Mezzion PharmaUdenafil
Phosphodiesterase 5A inhibitor
PDE5APhase 3Single Ventricle Heart Disease–
Beni-Suef Universitypentoxifylline
Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor
ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3APhase 3Embryo Transfer–
The University of Texas Medical Branch, GalvestonSildenafil Citrate
Phosphodiesterase 5A inhibitor
PDE5APhase 2Spinal Cord Injuries; Urinary IncontinenceDec 2026
Mostafa BahaaPentoxifylline
Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor
ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3APhase 2EpilepsyDec 2026
Yunfeng XiaDipyridamole
Equilibrative nucleoside transporter 1 inhibitor; 3',5'-cyclic phosphodiesterase inhibitor
SLC29A1, PDE5A, PDE4A, PDE3A, PDE6HPhase 2Restless Leg Syndrome Due to UraemiaDec 2026
Ihab Elsayed HassanPentoxifylline
Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor
ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3APhase 2Inflammatory Bowel DiseasesJan 2027
University Hospital, LimogesPentoxifylline
Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor
ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3APhase 2Medication-related Osteonecrosis of the Jaw (MRONJ)Apr 2027
Stanford UniversityDipyridamole
Equilibrative nucleoside transporter 1 inhibitor; 3',5'-cyclic phosphodiesterase inhibitor
SLC29A1, PDE5A, PDE4A, PDE3A, PDE6HPhase 2HypophosphatemiaMay 2027
University of AlbertaSildenafil Citrate
Phosphodiesterase 5A inhibitor
PDE5APhase 2Chronic Obstructive Pulmonary DiseaseMay 2027
University of PennsylvaniaSildenafil Citrate
Phosphodiesterase 5A inhibitor
PDE5APhase 2Traumatic Brain InjuryDec 2027
Silvia UlrichSildenafil
Phosphodiesterase 5A inhibitor
PDE5APhase 2Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)Apr 2028
M.D. Anderson Cancer CenterPentoxifylline
Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor
ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3APhase 2Lymphedema; Fibrosis SyndromeMay 2029
Pia WintermarkSildenafil
Phosphodiesterase 5A inhibitor
PDE5APhase 2Neonatal EncephalopathyOct 2030
University Health Network, TorontoPentoxifylline
Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor
ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3APhase 2Non-Small Cell Lung CancerNov 2031
University of UtahSildenafil
Phosphodiesterase 5A inhibitor
PDE5APhase 2Congenital Diaphragmatic Hernia–
Children's Mercy Hospital Kansas CitySildenafil
Phosphodiesterase 5A inhibitor
PDE5APhase 1Fontan CirculationMay 2027
Aspargo LabsASP-001.1 (Hezkue Turbo)
Phosphodiesterase-5 (PDE-5) inhibitor
PDE5APhase 1Erectile Dysfunction–
Sohag UniversitySildenafil Citrate
Phosphodiesterase 5A inhibitor
PDE5APhase 1Persistent Pulmonary Hypertension of Newborn–

Conditions

Erectile Dysfunction (3) Pulmonary Arterial Hypertension (PAH) (2) IVF (1) Acute Urinary Retention (1) Medication-related Osteonecrosis of the Jaw (1) Medication-related Osteonecrosis of the Jaw (MRONJ) (1) Erectile Dysfunction Following Radical Prostatectomy (1) Persistent Pulmonary Hypertension of Newborn (1) Fontan Circulation (1) Hypophosphatemia (1) Epilepsy (1) Lymphedema (1)

Modalities

small molecule (31)

Companies

Beni-Suef University (2) University of Sao Paulo General Hospital (1) University of Washington (1) University Hospital, Limoges (1) The Netherlands Cancer Institute (1) Sohag University (1) Children's Mercy Hospital Kansas City (1) Aspargo Labs (1) Stanford University (1) Mostafa Bahaa (1) M.D. Anderson Cancer Center (1) University Hospital, Rouen (1) Assistance Publique - Hôpitaux de Paris (1) Vastra Gotaland Region (1) VA Office of Research and Development (1) Mezzion Pharma (1) Mansoura University (1) Rennes University Hospital (1) University of Pennsylvania (1) Ihab Elsayed Hassan (1)

Related targets

PDE4A (14) PDE3A (14) ADORA2B (11) ADORA2A (11) SLC29A1 (3) PDE6H (3)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.